Friday, May 25, 2018
 
 
Company News: Page (1) of 1 - 05/17/18 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
Stock-Sector Releases Interview with CEO of Helomics Discussing Precision Medicine with Precision Therapeutics
CEO Gerald Vardzel explains in a Stock Sector interview the future of precision medicine.
(May 17, 2018)

NEW YORK, May 17, 2018 /PRNewswire-PRWeb/ -- Stock-Sector.com, an online source of news about promising medical, technology, and energy companies, today released an interview with Gerald Vardzel, President and CEO of Helomics.

In the interview Gerald Vardzel discusses the recent purchase of equity that Precision Therapeutics made into Helomics', as well as the fundamentals of Helomics' business model for precision medicine.

Headquartered in Pittsburgh, Pennsylvania, Helomics has established operations that bridge two emerging areas of the healthcare industry: precision medicine and big data. Helomics' competitive advantage lies in its proprietary D-CHIP™ database, which contains de-identified data compiled from more than a decade of clinical testing of tumor responses to drugs, coupled to an Artificial Intelligence (AI)-powered bioinformatics engine which generates actionable scientific insights from this rich data. These insights are used by BioPharma companies in the research and development of targeted cancer treatments for any given patient profile, driving improved patient outcomes.



About Precision Therapeutics Inc.

Precision Therapeutics (NASDAQ:AIPT) operates in two business areas: first, applying artificial intelligence to personalized medicine and drug discovery to provide personalized medicine solutions for clients in the pharmaceutical, diagnostic, and biotech industries, and second, production of the FDA-approved STREAMWAY® System for automated, direct-to-drain medical fluid disposal.

Stock-Sector is an online source of news about promising medical, technology, and energy companies. Stock-Sector was created out of necessity, to provide a glimpse of the financial markets in sectors relevant to the investor. We strive to deliver easily digestible content to the overburdened stockholder. Another significant focus of ours is to establish compelling media to heighten the experience in neglected humdrum industries.

The statements contained herein may include statements of future expectations and other forward-looking statements that are based on management's current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "potential," or "continue" and similar expressions identify forward-looking statements.

 

SOURCE Precision Therapeutics Inc.

Copyright 2014 PR Newswire. All Rights Reserved


Page: 1


Related Keywords:Business,Science,Financial,Medical,Biology,Computer Science,Cancer,Business,Other,
Related Sites: DMN Newswire ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   IBN - IT Weekly Newsletter ,   DMN Newswire Newsletter
 
 
 
 
 
 
 
Seniors

Drugs
  • Bellevue Asset Management AG: Bellevue launches dedicated digital health fund
  • Study on Poor Oral Hygiene Habits of Aging Population Underlines the Importance of Outstanding Dental Care, says Premier Care Dental Group
  • Blood Gas and Electrolyte Analyzer Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2023
  • Interventional Cardiology Devices Market to be worth US$11.16 bn by 2022, Says TMR
  • Medical Fluid Bags Market will register 6.5% CAGR to cross USD 4.4 billion by 2024: Global Market Insights, Inc.

    Cancer
  • Bavarian Nordic Announces Interim Results for the First Three Months of 2018
  • NASP Applauds Bipartisan Legislation Introduced to Reduce Drug Costs and Support Access for Seniors with Life-Threatening Specialized Conditions
  • Celgene Corporation Announces Additional $3 Billion Share Repurchase Authorization and Plans to Execute a $2 Billion Accelerated Share Repurchase Program
  • Moorestown Visiting Nurse Association joins the growing enTouch network in New Jersey
  • Achieve Life Sciences, Inc. Announces Reverse Stock Split
  •  
     
     
     
     
     





    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines